Log in

NASDAQ:RVMDBill.com Stock Price, Forecast & News

+1.21 (+5.45 %)
(As of 04/5/2020 01:20 PM ET)
Today's Range
Now: $23.43
50-Day Range N/A
52-Week Range
Now: $23.43
Volume372,470 shs
Average Volume429,082 shs
Market Capitalization$1.33 billion
P/E RatioN/A
Dividend YieldN/A
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.88 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:RVMD



Sales & Book Value

Annual SalesN/A



Market Cap$1.33 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive RVMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.

Bill.com (NASDAQ:RVMD) Frequently Asked Questions

How has Bill.com's stock been impacted by COVID-19 (Coronavirus)?

Bill.com's stock was trading at $29.67 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RVMD shares have decreased by 21.0% and is now trading at $23.43. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bill.com?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bill.com in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bill.com.

What price target have analysts set for RVMD?

4 Wall Street analysts have issued 12 month target prices for Bill.com's stock. Their forecasts range from $32.00 to $50.00. On average, they anticipate Bill.com's share price to reach $41.00 in the next twelve months. This suggests a possible upside of 75.0% from the stock's current price. View analysts' price targets for Bill.com.

Has Bill.com been receiving favorable news coverage?

Headlines about RVMD stock have been trending very negative on Sunday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bill.com earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutBill.com.

Who are some of Bill.com's key competitors?

What other stocks do shareholders of Bill.com own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bill.com investors own include Gossamer Bio (GOSS), Iovance Biotherapeutics (IOVA), Moderna (MRNA), Passage Bio (PASG), Selecta Biosciences (SELB), Schrodinger (SDGR), Aurinia Pharmaceuticals (AUPH), Athenex (ATNX), Ascendis Pharma A/S (ASND) and Ardelyx (ARDX).

Who are Bill.com's key executives?

Bill.com's management team includes the following people:
  • Dr. Mark A. Goldsmith M.D., Ph.D., CEO, Pres & Director (Age 58)
  • Ms. Margaret A. Horn, COO & Gen. Counsel (Age 57)
  • Dr. Stephen M. Kelsey M.D., FRCP, FRC Path., Pres of R&D (Age 59)
  • Dr. Martin D. Burke, Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael A. Fischbach, Academic Co-Founder & Member of Scientific Advisory Board (Age 39)

When did Bill.com IPO?

(RVMD) raised $150 million in an IPO on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

What is Bill.com's stock symbol?

Bill.com trades on the NASDAQ under the ticker symbol "RVMD."

When did the company's quiet period expire?

Bill.com's quiet period expired on Tuesday, March 24th. Bill.com had issued 14,000,000 shares in its IPO on February 13th. The total size of the offering was $238,000,000 based on an initial share price of $17.00. During the company's quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Bill.com?

Shares of RVMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bill.com's stock price today?

One share of RVMD stock can currently be purchased for approximately $23.43.

How big of a company is Bill.com?

Bill.com has a market capitalization of $1.33 billion.  View additional information about Bill.com.

What is Bill.com's official website?

The official website for Bill.com is http://www.revmed.com/.

How can I contact Bill.com?

Bill.com's mailing address is 700 SAGINAW DR, REDWOOD CITY CA, 94063. The company can be reached via phone at 415-766-3638 or via email at [email protected]

This page was last updated on 4/5/2020 by MarketBeat.com Staff

Featured Article: Margin

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel